Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in -Mutant Lung Adenocarcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Jun 17

PMID 34136375

Citations 7

Authors

Teng Li

Xiaocong Pang

Junyun Wang

Shouzheng Wang

Yiying Guo

Ning He

Puyuan Xing

Junling Li

Affiliations

Soon will be listed here.

Abstract

Background: Clinical evidence has shown that few non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor () mutations can benefit from immunotherapy. The tumor immune microenvironment (TIME) is a significant factor affecting the efficacy of immunotherapy. However, the TIME transformational process in -mutation patients is unknown.

Methods: The mRNA expression and mutation data and lung adenocarcinoma (LUAD) clinical data were obtained from The Cancer Genome Atlas (TCGA) database. Profiles describing the immune landscape of patients with mutations were characterized by differences in tumor mutation burden (TMB), ESTIMATE, CIBERSORT, and microenvironment cell populations-counter (MCP-counter).

Results: In total, the TCGA data for 585 patients were analyzed. Among these patients, 98 had mutations. The TMB was lower in the group (3.94 mut/Mb) than in the mutation group (6.09 mut/Mb, < 0.001) and the entire LUAD (6.58 mut/Mb, < 0.001). The group had a lower population of activated immune cells and an even higher score of immunosuppressive cells. A further inter-group comparison showed that differences in the TMB and tumor-infiltrating lymphocytes were only found between patients with oncogenic mutations and unknown mutation. Meanwhile, there were more myeloid dendritic cells (DCs) in 19del than in L858R-mutation patients and in common mutation patents than in uncommon mutation patients ( < 0.05). Additionally, we established a D score, where D = MCP-counter score for cytotoxic T lymphocytes (CTLs)/MCP-counter score for myeloid DCs. Further analysis revealed that lower D scores indicated immune suppression and were negatively related to several immunotherapy biomarkers.

Conclusions: The TIME of mutant NSCLC was immunosuppressive. Myeloid DCs gradually increased in 19del, L858R, and uncommon mutations. The potential role of CTLs and DCs in the TIME of patients requires further investigation.

Citing Articles

A heterogeneous tumor immune microenvironment of uncommon epidermal growth factor receptor mutant non-small cell lung cancer.

Zhang C, Yang L, Zhao W, Zhu H, Shi S, Chen S Cancer Sci. 2024; 115(9):3143-3152.

PMID: 38890815 PMC: 11462928. DOI: 10.1111/cas.16253.

MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma.

Bai L, Huo R, Fang G, Ma T, Shang Y Front Oncol. 2023; 13:1055122.

PMID: 36756152 PMC: 9900007. DOI: 10.3389/fonc.2023.1055122.

Machine learning and bioinformatics-based insights into the potential targets of saponins in smith against non-small cell lung cancer.

Wang Y, Huang X, Xian B, Jiang H, Zhou T, Chen S Front Genet. 2022; 13:1005896.

PMID: 36386821 PMC: 9649596. DOI: 10.3389/fgene.2022.1005896.

Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.

Zhang B, Zeng J, Zhang H, Zhu S, Wang H, He J Front Immunol. 2022; 13:974581.

PMID: 36159860 PMC: 9494286. DOI: 10.3389/fimmu.2022.974581.

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.

Madeddu C, Donisi C, Liscia N, Lai E, Scartozzi M, Maccio A Int J Mol Sci. 2022; 23(12).

PMID: 35742933 PMC: 9224267. DOI: 10.3390/ijms23126489.

References

Camidge D, Doebele R, Kerr K . Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019; 16(6):341-355. DOI: 10.1038/s41571-019-0173-9. View

Yang J, Shepherd F, Kim D, Lee G, Lee J, Chang G . Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. J Thorac Oncol. 2019; 14(5):933-939. DOI: 10.1016/j.jtho.2019.02.001. View

Kluger H, Tawbi H, Ascierto M, Bowden M, Callahan M, Cha E . Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J Immunother Cancer. 2020; 8(1). PMC: 7174063. DOI: 10.1136/jitc-2019-000398. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Sequist L, Yang J, Yamamoto N, OByrne K, Hirsh V, Mok T . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3327-34. DOI: 10.1200/JCO.2012.44.2806. View

Sharma S, Bell D, Settleman J, Haber D . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3):169-81. DOI: 10.1038/nrc2088. View

Mazzaschi G, Madeddu D, Falco A, Bocchialini G, Goldoni M, Sogni F . Low PD-1 Expression in Cytotoxic CD8 Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. Clin Cancer Res. 2017; 24(2):407-419. DOI: 10.1158/1078-0432.CCR-17-2156. View

Kulasinghe A, Taheri T, OByrne K, Hughes B, Kenny L, Punyadeera C . Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients. Front Oncol. 2021; 10:607349. PMC: 7851078. DOI: 10.3389/fonc.2020.607349. View

Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S . Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019; 20(5):625-635. DOI: 10.1016/S1470-2045(19)30035-X. View

10.

Wang H, Guo J, Shang X, Wang Z . Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation. Int Immunopharmacol. 2020; 84:106574. DOI: 10.1016/j.intimp.2020.106574. View

11.

Chen B, Khodadoust M, Liu C, Newman A, Alizadeh A . Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol. 2018; 1711:243-259. PMC: 5895181. DOI: 10.1007/978-1-4939-7493-1_12. View

12.

Lee C, Davies L, Wu Y, Mitsudomi T, Inoue A, Rosell R . Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. J Natl Cancer Inst. 2017; 109(6). DOI: 10.1093/jnci/djw279. View

13.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

14.

Lee C, Man J, Lord S, Cooper W, Links M, Gebski V . Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2017; 4(2):210-216. PMC: 5838598. DOI: 10.1001/jamaoncol.2017.4427. View

15.

Marinelli D, Mazzotta M, Scalera S, Terrenato I, Sperati F, DAmbrosio L . KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Ann Oncol. 2020; 31(12):1746-1754. DOI: 10.1016/j.annonc.2020.08.2105. View

16.

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

17.

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

18.

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

19.

Sturm G, Finotello F, Petitprez F, Zhang J, Baumbach J, Fridman W . Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 2019; 35(14):i436-i445. PMC: 6612828. DOI: 10.1093/bioinformatics/btz363. View

20.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View